The funds are part of the government’s $5 billion Project NextGen initiative to enable the rapid development of longer-lasting COVID-19 vaccines, a new antibody therapy and technologies to advance vaccine manufacturing processes, HHS said Tuesday.
ICON Government and Public Health Solutions, Pharm-Olam, Technical Resources Intl and Rho Federal Systems will collectively receive $1 billion to conduct clinical trials for new vaccines in partnership with the Biomedical Advanced Research and Development Authority.
Regeneron Pharmaceuticals will secure $326 million to create a next-generation monoclonal antibody therapy for COVID-19 prevention.
HHS will allocate $100 million to Global Health Investment Corp, a non-profit organization that invests in new technologies to accelerate responses to diseases and $10 million to Johnson & Johnson Innovation.
Nine companies win spots on Navy unmanned systems contract Work covers design, testing, deployment and sustainment support Autonomous maritime platforms…
Anthropic reportedly explores massive new funding round Anthropic deepens focus on AI-driven cyber defense and national security Its growth highlights…
Elsevier highlights growing impact of geopolitical tensions on research Governments face tension between security priorities and open science goals AI…
Deltek’s 2026 GovCon Clarity Report found contractors accelerating operations and AI adoption while struggling to maintain profitability and control. Kevin…
